Project Grant R21CA306039
Award Date 5/13/26
Completion Date 4/30/27
Dollars Obligated $412K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $733,864 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. Using high-throughput CRISPR-based screening...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $648,626 to the University of California, Irvine under the Cancer Treatment Research program (CFDA 93.395) on April 2, 2026, with a completion date of March 31, 2031. This award funds research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor-infiltrating regulatory T cells...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, Irvine $586,364 through the Cancer Biology Research program (CFDA 93.396) on April 7, 2026, for a five-year project grant extending through March 31, 2031. The research investigates Type 1 Innate Lymphoid Cells (ILC1s), including Natural Killer cells and ILC1s, and their anti-tumor mechanisms against acute myeloid leukemia (AML). Building on the principal investigator's 2022 Nature Immunology publication,...
- Federal Grant Award Summary The National Cancer Institute awarded a $588,289 Project Grant to the University of Chicago under the Cancer Biology Research program (CFDA 93.396) to investigate the non-apoptotic immunomodulatory mechanisms of BCL-2 family protein-targeting therapeutics in T cells. The award, effective May 1, 2026, through April 30, 2031, supports mechanistic research characterizing how BH3-mimetic drugs alter T cell function, plasticity, and mitochondrial dynamics. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Van Andel Research Institute (VAI) a Project Grant totaling $112,234 under the Cancer Research Manpower program (CFDA 93.398) to conduct investigator-initiated cancer immunotherapy research from August 1, 2025, through July 31, 2027. The grant supports research targeting the PTGIR (prostacyclin receptor)-prostacyclin signaling pathway to overcome CD8 T cell exhaustion and enhance anti-tumor immunity. The project aims to...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $3.18 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. Awarded on September 24, 2025, with a completion date of August 31, 2029, this research project will generate fundamental knowledge about how NK cells may suppress the efficacy of ICT in tumor treatment. The study will...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...